Title:
ENGINEERED IMMUNE CELL CO-EXPRESSING CCR2B, PREPARATION THEREFOR AND APPLICATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/046110
Kind Code:
A1
Abstract:
Provided is an engineered immune cell co-expressing CCR2b, wherein the engineered immune cell is a T cell or an NK cell. NKG2D extracellular domain-containing CAR molecules and CCR2b are co-expressed in a CAR-T cell, so that the sensitivity of the CAR-T cell to chemokines such as CCL2 and CCL7 can be improved by means of CCR2b, and efficient migration to colorectal cancer, ovarian cancer, pancreatic cancer and other lesions can be improved, thereby improving the treatment efficiency; in addition, various target antigens on the surfaces of colorectal cancer, ovarian cancer, pancreatic cancer and other cells can be recognized by means of NKG2D CAR molecules, thereby reducing the risk that the therapeutic effect is reduced due to tumor heterogeneity or target antigen loss, and improving the tumor treatment effect.
More Like This:
| JP2000516916 | [Title of Invention] A composition containing at least one nucleic acid. |
| WO/2000/077237 | 49 HUMAN SECRETED PROTEINS |
| WO/2024/061314 | TRANSPOSON SYSTEM AND APPLICATION THEREOF |
Inventors:
ZHANG XI (CN)
HUANG ZHIHONG (CN)
HAN DEPING (CN)
YAN NI (CN)
WANG TIAOXIA (CN)
ZHU XIAONA (CN)
WANG NING (CN)
LIN WEIXIONG (CN)
LU YONG (CN)
HUANG ZHIHONG (CN)
HAN DEPING (CN)
YAN NI (CN)
WANG TIAOXIA (CN)
ZHU XIAONA (CN)
WANG NING (CN)
LIN WEIXIONG (CN)
LU YONG (CN)
Application Number:
PCT/CN2022/121035
Publication Date:
March 30, 2023
Filing Date:
September 23, 2022
Export Citation:
Assignee:
GUANGZHOU BIOSYNGEN CO LTD (CN)
International Classes:
C12N5/10; A61K39/00; C07K16/28; C07K19/00; C12N15/13; C12N15/62; A61P35/00
Domestic Patent References:
| WO2020159941A1 | 2020-08-06 |
Foreign References:
| CN113621582A | 2021-11-09 | |||
| CN109777784A | 2019-05-21 | |||
| CN111378625A | 2020-07-07 | |||
| US20200308248A1 | 2020-10-01 | |||
| CN110872577A | 2020-03-10 | |||
| CN109153975A | 2019-01-04 | |||
| CN112961248A | 2021-06-15 | |||
| CN112142854A | 2020-12-29 | |||
| CN111632135A | 2020-09-08 |
Other References:
WANG YANAN, WANG JING, YANG XINYI, YANG JINLONG, LU PANPAN, ZHAO LIN, LI BOKANG, PAN HANYU, JIANG ZHENGTAO, SHEN XIAOTING, LIANG Z: "Chemokine Receptor CCR2b Enhanced Anti-tumor Function of Chimeric Antigen Receptor T Cells Targeting Mesothelin in a Non-small-cell Lung Carcinoma Model", FRONTIERS IN IMMUNOLOGY, vol. 12, 1 January 2021 (2021-01-01), pages 628906, XP093054444, DOI: 10.3389/fimmu.2021.628906
LIU TAO, LIANG WEIXIANG: "Ultrasound guided NKG2D-CAR gene therapy for advanced rectal cancer： a case report", JOURNAL OF CLINICAL ULTRASOUND IN MEDICINE, vol. 22, no. 9, 30 September 2020 (2020-09-30), XP093054631, ISSN: 1008-6978, DOI: 10.16245/j.cnki.issn1008-6978.2020.09.011
LIU TAO, LIANG WEIXIANG: "Ultrasound guided NKG2D-CAR gene therapy for advanced rectal cancer： a case report", JOURNAL OF CLINICAL ULTRASOUND IN MEDICINE, vol. 22, no. 9, 30 September 2020 (2020-09-30), XP093054631, ISSN: 1008-6978, DOI: 10.16245/j.cnki.issn1008-6978.2020.09.011
Attorney, Agent or Firm:
XU&PARTNERS, LLC. (CN)
Download PDF:
Previous Patent: PHASE SHIFTER AND PHASE SHIFTING METHOD
Next Patent: BASOPHIL ACTIVATION DETECTION METHOD AND APPLICATION THEREOF
Next Patent: BASOPHIL ACTIVATION DETECTION METHOD AND APPLICATION THEREOF